New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
10:00 EDTWAG, CVS, ABC, MCK, CTRX, ESRX, CAHLeerink's healthcare tech analyst holds an analyst/industry conference call
Healthcare Technology Analyst Larsen, along with MEDACorp Specialists Brian Anderson and Mary Beth Mulligan, discuss the quality of service and performance provided by each PBM (Pharmacy Benefit Manager) on an Analyst/Industry conference call. Relevant companies ABC, CAH, CTRX, CVS, ESRX, MCK and WAG may be included on the Analyst/Industry conference call to be held on March 31 at 11 am.
News For ABC;CAH;CTRX;CVS;ESRX;MCK;WAG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 27, 2015
07:20 EDTESRXJPMorgan positive on Express Scripts after management meetings
Subscribe for More Information
November 24, 2015
16:27 EDTABCAmerisourceBergen files automatic mixed securities shelf
Subscribe for More Information
November 23, 2015
14:10 EDTCVSAmgen's PCSK9 inhibitor Repatha gets exclusive deal with CVS
Subscribe for More Information
09:21 EDTCVSConsolidated Tomoka disposes non-core income property for about $5.4M
Subscribe for More Information
08:08 EDTESRXBarron's article on Express Scripts a mischaracterization, says JPMorgan
Subscribe for More Information
November 22, 2015
13:11 EDTESRXExpress Scripts' link to specialty drug makers presents new risk, Barron's says
Express Scripts' (ESRX) United BioSource unit -- often hired by specialty drug makers to help patients find money for costly treatments -- appears at odds with the company's role in negotiating lower drug prices, Barron's contends in a feature article. Though Express Scripts will continue to earn the "vast majority" of its profits as a pharmacy-benefit manager, Barron's argues that investors should view its work on behalf of specialty drug companies as a risk factor for the stock, particularly in light of recent Valeant (VRX) and Horizon (HZNP) headlines. Reference Link
November 20, 2015
18:58 EDTESRXExpress Scripts management to meet with JPMorgan
Meeting to be held in New York on November 24 hosted by JPMorgan.
07:55 EDTCAHCardinal Health shares look very attractive at current valuation, says Cowen
Cowen believes Cardinal Health shares look very attractive at current levels, citing its underlying organic growth, its operational margin targets and expectations for a deployment of capital for acquisitions. Cowen reiterated its Outperform rating and $102 price target on Cardinal Health shares.
November 19, 2015
16:35 EDTCAHCardinal Health presents four-year data from VEITHsymposium INNOVATION Trial
Subscribe for More Information
November 18, 2015
15:40 EDTESRX, CVSCongressman says U.S. may need look at pharmacy competition, dealReporter says
Subscribe for More Information
11:01 EDTCVSTarget says working with CVS team to secure regulatory approval for deal
Target (TGT) says "pleased" with progress to date of CVS (CVS) deal.
06:59 EDTCAHCardinal Health to host analyst and investor day
Subscribe for More Information
06:46 EDTABCAmerisourceBergen announces Steven Collis to succeed Richard Gozon as Chairman
AmerisourceBergen announced that, following Richard Gozon's retirement as Chairman of the Board at the annual meeting of stockholders in March 2016, Steven Collis, President and CEO, will succeed Gozon as Chairman of the Board, and Jane Henney, will become the board's Lead Independent Director. The election of Collis and Henney is contingent on their re-election as directors at the annual meeting of stockholders scheduled to be held on March 3, 2016.
November 17, 2015
10:17 EDTESRX, CVSHouse Judiciary Committee to hold a hearing
The Subcommittee on Regulatory Reform, Commercial and Antitrust Law holds a hearing entitled, "The State of Competition in the Pharmacy Benefit Manager and Pharmacy Marketplaces" with Vice President Bricker of Express Scripts and Senior Vice President Pons of CVS Health on November 17 at 3 pm. Webcast Link
07:27 EDTABCAmerisourceBergen reinstated with an Outperform at Credit Suisse
Subscribe for More Information
November 16, 2015
10:00 EDTABCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alliant Energy (LNT) upgraded to Outperform from Market Perform at Wells Fargo... AmerisourceBergen (ABC) upgraded to Equal Weight from Underweight at Morgan Stanley... Amphenol (APH) upgraded to Buy from Neutral at Goldman... CA Technologies (CA) upgraded to Neutral from Sell at Citi... Cempra (CEMP) upgraded to Overweight from Equal Weight at Morgan Stanley... Edgewell Personal Care (EPC) upgraded to Neutral from Sell at Goldman... Eli Lilly (LLY) upgraded on improved growth outlook at BMO Capital... MiMedx (MDXG) upgraded to Strong Buy from Buy at Needham... NVIDIA (NVDA) upgraded to Buy from Hold at Canaccord... New York REIT (NYRT) upgraded to Buy from Hold at Evercore ISI... Oracle (ORCL) upgraded to Conviction Buy from Buy at Goldman... Perrigo (PRGO) upgraded to Buy from Neutral at UBS... Semtech (SMTC) upgraded to Buy from Neutral at B. Riley... Tullow Oil (TUWOY) upgraded to Buy from Neutral at UBS... Wabtec (WAB) upgraded to Outperform on valuatoin at Raymond James.
09:59 EDTMCKOmega bought Valeant in Q3, sold some SuneEdison
Leon Cooperman's Omega Advisors gave a quarterly update on its stakes in a filing this morning, disclosing its positions as of September 30. NEW STAKES: Pfizer (PFE), Valeant (VRX) Walgreens Boots Alliance (WBA), TerraForm Global (GLBL), Cigna (CI). INCREASED STAKES: Google Class A (GOOGL), Facebook (FB), Delta Air Lines (DAL). DECREASED STAKES: SunEdison (SUNE), Shire (SHPG), Citi (C), KAR Auction (KAR), LyondellBasell (LYB). LIQUIDATED STAKES: McKesson (MCK), 21st Century Fox (FOXA), General Motors (GM), QEP Resources (QEP), eBay (EBAY).
09:06 EDTCVS, ESRXDiplomat seen as compelling amid specialty pharmacy fallout
Shares of specialty pharmacy operator Diplomat Pharmacy (DPLO) and pharmacy benefit manager Express Scripts (ESRX) have each been knocked down by the negative news surrounding the sector amid the troubles faced by Valeant (VRX) and others, but an analyst at Leerink contends in a note to investors that the pullbacks in both stocks provide buying opportunities. BACKGROUND: Drugmaker Valeant and its prior specialty pharmacy partner, Philidor Rx Services, have been at the center of the firestorm engulfing the sector. Following claims that Philidor urged its employees to modify prescriptions to ensure more orders of Valeant-branded drugs rather than generics, as well as other allegations of wrongdoing, Express Scripts (ESRX) and peer CVS Health (CVS) terminated Philidor from their networks. The day after those termination announcements, Valeant said that it was severing all ties with Philidor and that the pharmacy planned to shut down operations as soon as possible, consistent with applicable laws. Valeant has subsequently said that Philidor has committed to cease operations by January 30, 2016, at the latest. More recently, Express Scripts, the nation's largest pharmacy benefit manager, announced that it stopped doing business with Linden Care, accusing it of being a "captive" pharmacy that dispenses mostly products made by Horizon Pharma (HZNP). In turn, Horizon called the idea that Linden Care is a captive pharmacy "entirely false," stating that "at best Express Scripts is being reckless in its allegations and at worse it is intentionally attempting to mislead investors." Express Scripts' move also impacted shares of Insys Therapeutics (INSY), which reportedly also used Linden Care to fulfill prescription for its drugs. DIPLOMAT LIKELY TO STAY IN-NETWORK: Leerink analyst David Larsen acknowledged that recent events indicate that Express Scripts appears to be evaluating certain retail pharmacies and their relationships with manufacturers, but he believes Diplomat's mix of drugs for diseases like multiple sclerosis, HIV, hepatitis C and cancer differentiate it as a "true" specialty pharmacy. Larsen does not think Diplomat is at risk of being excluded from the pharmacy networks of Express Scripts, CVS or UnitedHealth's (UNH) Optum, he tells investors. Larsen expects limited distribution agreements to stay an important channel strategy for drugmakers and believes these agreements are appropriate for high cost specialty drugs that require special handling and additional services to manage patient adherence. The analyst, who thinks Diplomat remains well positioned to deliver annual growth of over 30% in the next several years, keeps an Outperform rating on its shares. EXPRESS BUYING OPPORTUNITY: Larsen also thinks concerns around manufacturer and pharmacy relationships have put unwarranted pressure on shares of Express Scripts. He does not expect Express Scripts to disclose new lawsuits around rebate dollars owed over other manufacturer disputes and keeps an Outperform rating on the stock, which he views as having an "attractive" valuation. WHAT'S NOTABLE: Larsen also thinks that the specialty channel remains an opportunity for Walgreens Boots Alliance (WBA) and believes its proposed acquisition of Rite Aid (RAD) can strengthen its specialty offering. The analyst keeps an Outperform rating on Walgreens shares as well. PRICE ACTION: Over the last three months, Diplomat Pharmacy shares have declined 28%, Express Scripts has fallen 6% and Walgreens has dropped 14%.
08:06 EDTABCAmerisourceBergen upgraded to Equal Weight from Underweight at Morgan Stanley
Subscribe for More Information
06:18 EDTCVS, ESRXDiplomat Pharmacy selloff brings 'compelling' entry point, says Leerink
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use